依鲁替尼+BR的安全性与已知的BR和依鲁替尼一致。
Safety of br + ibr was consistent with the known profiles for br and ibr.
依鲁替尼的平均剂量强度高可改善PFS，漏服一周以上剂量的患者PFS较长。
A higher mean dose intensity of ibr is associated with improved PFS, with patients missing more than 1 week of treatment experiencing more PFS events.
依鲁替尼——首创药物，每天口服一次，布鲁顿酪氨酸激酶（BTK）的共价抑制剂——口服给药之后可快速从浆细胞内清除。
Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).
依鲁替尼——首创药物，每天口服一次，布鲁顿酪氨酸激酶（BTK）的共价抑制剂——口服给药之后可快速从浆细胞内清除。
Ibrutinib (ibr), a first-in-class, once-daily, oral, covalent inhibitor of Bruton's tyrosine kinase (BTK), is rapidly eliminated from plasma after oral administration (Advani, JCO 2013).
应用推荐